Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Melanoma 74Hodgkin Disease 56Lymphoma 22Sarcoma 13Neoplasm Metastasis 11Leiomyosarcoma 8Uveal Melanoma 7Neoplasms 7Skin Neoplasms 6Neuroblastoma 4Sarcoma, Synovial 3Recurrence 3Solitary Fibrous Tumors 2Sarcoma, Alveolar Soft Part 2Hematologic Diseases 2HIV Infections 2Thyroid Neoplasms 1Solid Tumor 1Small Cell Lung Carcinoma 1Skin Diseases 1Sarcoma, Ewing 1Sarcoma, Clear Cell 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Parathyroid Neoplasms 1Osteosarcoma 1Oligodendroglioma 1Neurofibrosarcoma 1Neuroendocrine Tumors 1Melanoma, Cutaneous Malignant 1Melanoma Neoplasms 1

Interventions

lutetium Lu 177 dotatate 34Everolimus 33lanreotide 13gallium Ga 68 dotatate 13Temozolomide 13Magnetic Resonance Spectroscopy 13Nivolumab 12pembrolizumab 11Octreotide 11Capecitabine 11177Lu-octreotide, DOTA(0)-Tyr(3)- 10cabozantinib 9Positron Emission Tomography Computed Tomography 93-Iodobenzylguanidine 9surufatinib 8Sunitinib 8Specimen Handling 7Carboplatin 7pasireotide 6amino-acid, glucose, and electrolyte solution 690Y-octreotide, DOTA-Tyr(3)- 6lenvatinib 5Lutetium-177 5Ipilimumab 5Fluorodeoxyglucose F18 5Etoposide 5Cisplatin 5Bevacizumab 5telotristat ethyl 4olaparib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neuroendocrine Tumors × Dacarbazine × Clear all
NCT03279601 2017-09-12

Study to Compare Capecitabine Combined With Dacarbazine(CAPDTIC) Versus Capecitabine Combined Temozolomide(CAPTEM) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Tumor

Peking University

Phase 2 Unknown
148 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡